A decade ago a hypothesis introduced to explain tardive dyskinesia (TD) implicated free radicals generated secondary to neuroleptic treatment. Since then many preclinical and clinical studies have investigated this possibility. These studies suggest that free radicals are probably involved in the pathogenesis of TD and that vitamin E could be efficacious in its treatment.
Tardive dyskinesia (TD) is a syndrome of late-onset, abnormal, choreoathetoid involuntary movements that develops in some patients who receive chronic neuroleptic medications. These involuntary movements most commonly involve the perioral area and tongue, but they can involve almost any muscle group, including those of the extremities, the trunk, and even the diaphragm. The average prevalence of TD is estimated to be about 20 to 30 percent in patients treated with long-term neuroleptics. A prospective study by Kane et al. (1988) estimated the incidence of TD to be roughly 5 percent in the first year with a steady increase of about 5 percent per year, so that after 5 years, 25 percent of patients had met diagnostic criteria for TD. Another study, by Glazer et al. (1993) , estimated the risk for TD in psychiatric patients on neuroleptic medication to be 32 percent after 5 years, 57 percent after 15 years, and 68 percent after 25 years. These and other studies indicate that there is a strong association between TD and the length of time a patient is exposed to neuroleptics. Other risk factors for TD are older age, especially postmenopausal women; the presence of affective symptoms; diabetes; and organic brain damage (Jeste and Wyatt 1982 ; APA Task Force on Tardive Dyskinesia 1992; Khot et al. 1992 ).
The Neurodegenerative Hypothesis ofTD
There are a number of hypotheses about the etiopathology of TD (Jeste and Wyatt 1982; Khot et al. 1992 ), but we have chosen to focus on the neurodegenerative hypothesis, which was proposed in the mid-1980s and suggests that persistent TD may be associated with, or induced by, neuronal damage somewhere in the basal ganglia. Fibiger and Lloyd (1984) proposed that neuroleptics damage gamma-aminobutyric acid (GABA) neurons in the basal ganglia. In theory, these damaged neurons in turn release the inhibitory effects that GABA neurons have on the dopaminergic output neurons in the nigrostriatal tract, possibly leading to a state of dopamine excess or hyperfunction in the basal ganglia.
Building on that hypothesis, Cadet and Lohr (1989) proposed that the damage, which could affect the neuronal membrane function and, if unchecked, could lead to cell death, might involve the presynaptic catecholaminergic fibers as well as other neurotransmitter systems. They also proposed that these neuronal changes were secondary to free radical generation from increased dopamine metabolism and turnover, a consequence of neuroleptic medication. Dopamine is primarily metabolized through oxidation by monoamine oxidase to 3,4-dihydroxyphenyl-acetic acid (DOPAC). This reaction produces hydrogen peroxide (H 2 O 2 ). Dopamine is also metabolized by auto-oxidation, yielding the superoxide radical (O2"). Hydrogen peroxide can further react with iron or copper ions to produce the hydroxyl radical (OH"), which is the most toxic of free radicals. Increased dopamine turnover caused by neuroleptics could lead to excessive production of these potentially damaging free radicals. At some point, a threshold might be reached, and the antioxidant defense system (which includes catalase, superoxide dismutase (SOD), and the glutathione enzyme complex peroxidase/reductase as well as antioxidants such as vitamin E) would be overwhelmed. Ultimately, this process could lead to neuronal membrane instability and perhaps cell death (figure 1).
The idea that oxidative stress and free radicals may play a role in some neuropsychiatric diseases with an underlying neurodegenerative process has recently achieved some prominence. Two reviews (Coyle and Puttfarcken 1993; Olanow 1993 ) outline the possible role of free radicals in the pathogenesis of Huntington's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, strokes, and seizures.
More recently, several lines of evidence have been proposed to indicate involvement of free radicals in the pathology of schizophrenia: (1) neuronal membrane damage, (2) dysregulation of the antioxidant enzyme cascade, and (3) increased indices of lipid peroxidation in association with relapse (Mahadik and Mukherjee 1996; Reddy and Yao 1996) . These abnormalities have been associated with computerized tomography (CT) scan abnormalities, negative symptoms, and TD (Reddy and Yao 1996) .
The neurodegenerative hypothesis of TD derives support from different lines of evidence, including preclinical studies suggesting that neuroleptics may have a cytotoxic effect. In addition, some clinical studies have shown (1) some neuropathological changes in the basal ganglia, (2) biochemical changes possibly indicative of oxidative stress in patients with TD, and (3) the effectiveness of antioxidants in treating TD through medication trials. These preclinical and clinical studies are reviewed below.
Preclinical Studies
Since it is assumed that TD is caused by neuroleptic medications, advocates of a possible cytotoxic mechanism have investigated the effect neuroleptics may have on neuronal function and anatomy. Munyon et al. (1987) studied the possible in vitro effects of different neuroleptic drugs on the shape and protein synthesis of human glioma cells and found that exposing these cells to neuroleptics caused the withdrawal of their cytoplasmic processes, leaving them spherical in shape. Neuroleptics were also found to inhibit the incorporation of thymidine into deoxyribonucleic acid (DNA). These two effects were reported to inhibit cell viability. The authors also reported that, of all the neuroleptics they tested, the phenothiazines were the most potent in exhibiting these 
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Lipid Peroxidation -•Cell Death effects, while molindone was the least potent. Similar findings were reported by Behl et al. (1995) , who found that hippocampal neurons and glioma cells showed DNA degradation and cell lysis after 24-hour incubation with haloperidol. These changes were prevented by the addition of vitamin E. In another study, Jeste et al. (1991) looked at the effects of fluphenazine on neuronal cell density in the striatum. Rats were treated with fluphenazine and sacrificed at 4, 8, and 12 months of treatment. Results showed that after 4 months of treatment there was no observed difference between the vehicle-treated and neuroleptic-treated rats. After 8 months of treatment, the rats that had been given neuroleptics had a lower density of large neurons. After 12 months of treatment, however, both groups of rats showed very low neuronal density. This was attributed to a possible aging effect on neuronal loss that could overshadow the neuroleptic effect, and the fact that neuroleptic treatment could accelerate the natural process of cell loss.
To investigate other possible direct cytotoxic effects of neuroleptic medications, Subramanyam et al. (1990 Subramanyam et al. ( , 1991 , Fang and Gorrod (1991) , and Gorrod and Fang (1993) studied the metabolism of haloperidol by hepatic microsomes. They reported that haloperidol has a metabolic pathway similar to that of the neurotoxic compound MPTP (1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine), yielding the 1,2,3,6,-tetrahydropyridine analogue of haloperidol, HTP. Like MPTP, which is metabolized to MPP + , HTP is further metabolized to the pyridinium metabolite HP + . This finding raises the possibility that haloperidol may produce motor neurotoxicity by a mechanism similar to MPTP because it is thought that the conversion of MPTP to MPP + is responsible for the Parkinson-like symptoms in the MPTP animal model of the disease. The question remains open as to whether other neuroleptics have similar metabolic pathways, which would be important if the production of MPP + -like compounds is involved in TD.
To further investigate this issue, Burkhardt et al. (1993) studied the in vitro effect of neuroleptics on mitochondrial functions in rat brain. Their interest was based on the structural similarities between the haloperidol metabolite HP + and MPP + , and the fact that MPP + exerts its toxic effect by interfering with cell respiration through inhibition of complex I of the electron transport chain. They reported that, like MPP + , haloperidol, chlorpromazine, and thiothixene inhibited complex I of the electron transport chain. Clozapine was also found to inhibit complex I, but at a much higher concentration than the typical neuroleptics. This inhibition was discussed as a possible factor in the development of extrapyramidal symptoms (EPS) and TD, since similar inhibition was reported by the same group in diseases like Huntington's and Parkinson's.
To look for evidence of oxidative stress on brain cells due to neuroleptics, Ravindranath (1992, 1993) studied the effects on glutathione homeostasis and lipid peroxidation of acute and chronic administration of haloperidol to rats. They found a significant decrease in glutathione levels in the cortex, striatum, and midbrain after a single injection of haloperidol. Following chronic administration of haloperidol in the drinking water, animals were sacrificed at 1, 2, 3, and 6 months. Compared with controls, haloperidol-treated animals showed a significant increase in thiobarbiturate reactive substances (TBARS). These substances are the by-products of lipid peroxidation in the cortex, striatum, and midbrain. The changes were observed for up to 3 months, but levels dropped at 6 months. Similarly, there was a significant increase in oxidized glutathione levels. These findings suggest that after prolonged administration of haloperidol, the homeostasis of glutathione is largely restored and lipid peroxidation by-products are reduced. Jackson- Lewis et al. (1991) studied the effects of fluphenazine on monoamine metabolism in the rat brain and reported (1) significant increases of dopamine in the nucleus accumbens; (2) significant decreases in DOPAC in the frontal cortex, nucleus accumbens, and hippocampus; and (3) decreased homovanillic acid (HVA) in the striatum. Coadministration of vitamin E prevented these changes. Jackson-Lewis et al. suggested that the electrophysiological changes observed in nigral cells after chronic exposure to neuroleptics may be secondary to the cytotoxic effect induced by free radicals on these cells, and that vitamin E could prevent these changes by neutralizing the free radicals.
We (Elkashef et al., in preparation) administered haloperidol 1 mg/kg/day i.m. to rats for a total of 8 months. Three months after the start of haloperidol injections, a subgroup developed vacuous chewing movements. The movements persisted until the rats were sacrificed 5 months later. We looked for evidence of increased free radical production in these animals by measuring TBARS. We found that the rats with vacuous chewing movements had significantly higher TBARS production in the striatum, suggesting increased lipid peroxidation and free radical production. This is probably the first evidence of free radical production in the TD rat model.
Clinical Studies
Neuropathological Studies. Postmortem studies have reported neuronal loss and gliosis in the basal ganglia of patients with TD. Christensen et al. (1970) reported signs of neurodegeneration in the substantia nigra of 27 out of 28 patients with oral dyskinesia. Twenty-one of those 28 patients had received neuroleptic medication, compared with 7 of 28 psychiatric controls who did not have TD. They also reported brain stem gliosis in 25 of the patients compared with 4 of the controls. Jellinger (1977) reported gliosis and swelling of the large neurons of the caudate in 5 out of 9 patients with TD compared to 1 of 14 controls. Gross and Kaltenbach (1968) reported lesions in the caudate of 3 patients with TD, and 1 patient had similar lesions in the substantia nigra. Other case reports have found similar changes in different basal ganglia structures in patients with TD (Dynes 1970; Jamielity 1976; Ule and Struwe 1978) . Except for those by Christensen et al. and Jellinger, these studies are limited by the small number of cases and the lack of control groups. More generally, postmortem studies are complicated by methodological issues such as (1) antemortem psychiatric diagnosis, (2) diagnosis of TD, (3) cause of death, (4) the period between time of death and brain collection, and (5) the sensitivity of the techniques employed.
Structural changes have also been reported in one CT study. Patients with TD were found to have smaller heads of the caudate and lenticular nuclei and increased bicaudate distance (Bartels and Themelis 1983) . In contrast, another CT study found no significant differences in the bifrontal/bicaudate ratio between TD patients and matched psychiatric controls (Jeste et al. 1980) . Some postmortem studies have reported that schizophrenia patients receiving chronic neuroleptic treatment had larger basal ganglia structures than normal controls (Heckers et al. 1991) . Iron concentrations in the basal ganglia of patients with TD is of particular interest since chronic treatment with neuroleptics has been reported to cause increased iron concentration in the basal ganglia (Drayer 1987; Casanova et al. 1990 Casanova et al. , 1992 . This increase in iron could lead to increased production of hydroxyl radicals through interactions with hydrogen peroxide, which is a by-product of increased dopamine turnover and its metabolism by monoamine oxidase (MAO) (see figure  1) . While Campbell et al. (1985) reported increased iron deposition in the basal ganglia of one patient with TD, the other studies have yielded essentially negative results (Hunter etal. 1968) .
MRI studies (Jernigan et al. 1991; Breier et al. 1992; Swayze et al. 1992; Elkashef et al. 1994a) have also reported that patients with schizophrenia receiving chronic neuroleptic treatment had larger basal ganglia structures than normal controls. Only two of these MRI studies, however, observed patients with TD. One study (Mion et al. 1991) found that schizophrenia patients with TD had smaller caudate volumes compared with those without TD. The other MRI study (Elkashef et al. 1994Z?) found no statistically significant difference in the volumes of basal ganglia structures between schizophrenia patients with or without TD. MRI studies of iron concentrations have also yielded mixed results. Increased iron deposition can cause decreased signal intensity and shortening of the relaxation time on MRI (Drayer et al. 1986 ). Of the three MRI studies investigating iron deposition in the basal ganglia of patients with TD, two reported no change in the signal (Heinz et al. 1988; Elkashef et al. 1994fc ) and one (Bartzokis et al. 1990 ) reported shortened relaxation time in the left caudate of patients with TD. These studies suggest an underlying process other than aging that leads to neurodegeneration in the brains of schizophrenia patients with TD, but the studies don't directly provide evidence that it is mediated by free radical generation.
Biochemical Studies. Several investigators have attempted to determine if there is increased lipid peroxidation in patients with TD as well as oxidative stress-induced changes in the levels or activities of various antioxidant enzymes. Lohr et al. (1990) measured cerebrospinal fluid (CSF) levels of TBARS and conjugated dienes, another by-product of lipid peroxidation, as well as HVA, DOPAC, the norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG), and the serotonin metabolite 5-hydroxyindoleacetic acid (5-HI A A) in 10 patients with and 16 patients without TD. They reported that patients with TD had significantly higher levels of conjugated dienes and a trend for higher TBARS levels than the patients without TD. They also reported a significant positive correlation between the concentration of the conjugated dienes and the severity of TD, and a significant positive correlation between the concentration of TBARS and DOPAC. These findings are limited by the problems encountered using TBARS assay in clinical application. The problems are (1) limited sensitivity and reproducibility, (2) sample instability, and (3) drug interference. Peet and Laugharne (1993) reported a highly significant positive correlation between the severity of TD and the plasma levels of TBARS in 14 patients with TD. Pai et al. (1994) measured the concentration of glutathione and the lipid peroxidation product malondialdehyde in the CSF of drug-naive, acutely psychotic patients before and 2 weeks after treatment with haloperidol. They reported that the levels of glutathione significantly decreased after 2 weeks of haloperidol treatment, and, concomitant with this decrease, there was a marked increase in malondialdehyde. These results suggest, as they did in the preclinical studies, that lipid peroxidation is associated with acute treatment with haloperidol. Pall et al. (1987) measured CSF levels of TBARS and conjugated dienes in 9 nonpsychiatric patients who were receiving phenothiazines and in a control group of patients matched for age, gender, and diagnosis. They reported significant elevations of both TBARS and conju-gated dienes in the phenothiazine group, with the highest elevations seen in patients with EPS. In a study of 128 schizophrenia patients, McCreadie et al. (1995) measured plasma lipid peroxide, a by-product of free radical damage to lipids, and serum vitamin E levels in patients with and without TD and in normal controls. They reported that patients with schizophrenia have a higher level of lipid peroxide and lower serum vitamin E levels than normal subjects. They report no differences, however, between patients with and without TD. They later discuss that this could be due to a discrepancy between blood and brain free radical activity or to the fact that the patients they studied were chronically ill and that the levels of free radicals change acutely but perhaps tend to stabilize after chronic adaptation. This latter argument is consistent with the Ravindranath (1992, 1993) finding in rats chronically treated with neuroleptics; however, it doesn't explain the reported differences between the patients and normal subjects. Goff et al. (1995) studied the relationship among tardive dyskinesia; neuroleptic medication; and CSF concentrations of alanine, aspartate, lactate, and pyruvate. The study showed that neuroleptic treatment was associated with elevated CSF alanine, and that TD was associated with elevated aspartate regardless of medication status. It was suggested that these findings indicate underlying mitochondrial damage or dysfunction involving complex I activity secondary to neuroleptic medication.
Antioxidant Medication Trials.
Because neuroleptics induce lipid peroxidation and increase free radical production, it was thought that a trial of vitamin E, a potent antioxidant, would reduce abnormal movements in patients with TD. The first such study was conducted by Lohr et al. (1987) . Fifteen patients with persistent TD of relatively short duration were treated with a total of 1200 IU/day of vitamin E for 6 weeks in a double-blind, placebo-controlled fashion. There was significant improvement in TD following vitamin E treatment, with a mean reduction in movements of 43 percent. Seven patients improved more than 50 percent. This finding was replicated by Elkashef et al. (1990) in another placebocontrolled, double-blind study of 8 patients with TD. Patients showed significant improvement after receiving 1,200 IU/day of vitamin E for 4 weeks compared with placebo. Five of the patients had a mean improvement of 30 percent.
In another study, Schmidt et al. (1991) treated 19 patients with TD with 1200 IU/day of vitamin E in a double-blind, crossover design and found no effect. The vitamin E was given for only 14 days, however, and studies indicate that raising brain levels may take much longer. Similarly, Shriqui et al. (1992) reported negative findings in their study of 27 patients treated with 1200 IU/day of vitamin E in a 6-week, double-blind crossover study. In explaining the negative finding in their discussion, the authors suggest that it may have been due to the fact that 21 patients were on injectable depot neuroleptic medication (fluphenazine) and that the assessment for TD was done immediately before their next neuroleptic injection. This may have led to the emergence of withdrawal TD. They also suggest that another possible explanation for the negative finding is that most patients in the study had suffered from severe TD for an unspecified period of time. Egan et al. (1992) studied the effect of vitamin E in a group of 18 patients with TD in a double-blind crossover fashion. Although the overall effect was negative, 9 patients who had mild TD of relatively short duration (< 5 years) showed significant improvement in their TD after receiving vitamin E compared with placebo. Peet and Laughorne (1993) studied the effects of vitamin E in 14 patients with TD and reported a significant reduction of movements after 1 month of treatment with 1200 IU/day of vitamin E. That improvement was maintained for up to 13 months. In a similar study, Akhtar et al. (1993) treated 32 patients with TD with 1200 IU/day of vitamin E for 4 weeks and reported significant reduction in the TD ratings. Adler et al. (1993) treated 28 patients with TD with 1600 IU/day of vitamin E in a double-blind, parallel-group comparison, and reported significant improvement in TD movements. Lam et al. (1994) treated 12 patients with vitamin E 1200 IU/day for 6 weeks with no reported improvement in TD movements. The authors attribute the negative finding to the possibility that their patients were chronically ill and probably had had TD for a long period. Dabiri et al. (1994) , on the other hand, reported significant improvement in TD, averaging about 36 percent improvement in patients with TD treated for 10 weeks with 1200 IU/day of vitamin E. The most recent of the vitamin E trials in TD was by Lohr and Caligiuri (1996) , who attempted to replicate the Lohr et al. study (1987) . They treated 17 patients with vitamin E 1600 IU/day for 8 weeks, and reported significant improvement in TD, averaging 24 percent improvement, with 5 patients showing reduction in TD of more than 33 percent.
Of a total of 11 published studies investigating the effect of vitamin E on TD, 7 reported significantly positive effects, 3 were negative, and 1 lent support to the idea that a subgroup of patients with TD, specifically those with mild TD of relatively short duration, could benefit from vitamin E (see table 1 ).
Other medication trials have focused on selegiline, a selective MAO-B inhibitor and antioxidant. Goff et al. (1993) found selegiline to be less effective than a placebo in a 6-week trial of 33 patients with TD. In another dou- ble-blind study (Stearns et al., submitted) , 11 patients were given selegiline 10 to 15 mg/day for 8 weeks with no observed change in TD. The authors attribute the negative findings to the dopamine agonist effects associated with selegiline.
Comments
The basic studies reviewed above suggest that neuroleptics contribute to increased lipid peroxidation and free radical production. Except for one study, however, they failed to show a direct link between the cytotoxic effects of neuroleptics and TD, and most used one neuroleptic agent, haloperidol. The clinical studies suggest that the increase in lipid peroxidation and free radical production associated with neuroleptic treatment correlate positively with TD, and that the abnormal movements of TD can be decreased by administration of the antioxidant vitamin E. This may explain why TD appears to be reversible with an antioxidant. The elderly population and postmenopausal women were mentioned as more vulnerable to developing TD. The reason for increased vulnerability may be impaired mitochondrial respiratory function, which is reported with aging. This impaired function could result in the accumulation of unchecked free radicals (Wallace 1992) and to loss of the estrogen neuroprotective effect in postmenopausal women. Estrogen was reported to have a neuroprotective effect against the neurotoxin MPTP (Dluzen et al. 1996) , which may connect these risk factors of TD to the free radical hypothesis.
Two issues remained unanswered by the free radical theory. The first was why the severity of TD tended not to progress over time and the second was why every patient exposed to neuroleptics did not get TD. One explanation for the first issue is that the hypothesized increase in free radicals and the subsequent neuronal damage may happen early on with the introduction of neuroleptic medication. Antipsychotics are known to increase dopamine turnover and metabolism, which could explain the possible surge of free radical production around that time. With chronic treatment, however, neuronal depolarization block sets in, with stabilization of free radical production and possibly also upregulation of the free radical neutralizing enzyme cascade. In support of this explanation is the reported increased incidence of TD with the number of medication-free periods Kane 1995) . It may be that a surge of free radicals occurs with each reintroduction of neuroleptic medication, which in turn could explain the increased incidence of TD with the number of medication-free periods. This speculation is also consistent with the data reported above Ravindranath 1992, 1993; McCreadie et al. 1995) . The second issue-the fact that not all patients on neuroleptics develop TD-could be explained on the basis of (1) individual variation in the duration of exposure to neuroleptics, (2) the number of drug-free periods, (3) age and sex, and (4) genetic variation in the competence of the antioxidant defense system. Taken collectively, these data raise the obvious question of prevention. Can we prevent the development of TD by administering vitamin E as soon as treatment with neuroleptics begins? The answer to this question will have to await the results of clinical trials that address the issue. In one animal study, however, Gattaz et al. (1993) reported that simultaneous administration of vitamin E and haloperidol to rats prevented the development of the apomorphine-induced oral stereotypies seen in the haloperidol-only treated rats. This report is very encouraging regarding the possible preventive role of vitamin E therapy for TD.
